251. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants.
- Author
-
Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Bernardi S, Amicosante M, Di Cesare S, Castelli-Gattinara G, Wahren B, and Rossi P
- Subjects
- Amino Acid Sequence, Drug Administration Schedule, HIV Infections virology, Humans, Infant, Lymphocyte Activation, Molecular Sequence Data, Peptides chemistry, Treatment Outcome, gag Gene Products, Human Immunodeficiency Virus chemistry, nef Gene Products, Human Immunodeficiency Virus chemistry, tat Gene Products, Human Immunodeficiency Virus chemistry, Antiretroviral Therapy, Highly Active, HIV Infections drug therapy, HIV Infections immunology, HIV-1 immunology, Infectious Disease Transmission, Vertical, T-Lymphocytes immunology
- Abstract
Antiviral T-cell immune responses appear to be crucial to control HIV replication. Infants treated before the third month of life with highly active antiretroviral treatment (HAART) did not develop a persistent HIV-specific immune response. We evaluated how delayed initiation of HAART after 3 months of age influences the development of HIV-1-specific T-cell responses during long-term follow-up in 9 HIV-1 vertically infected infants. These data suggest that a longer antigenic stimulation, due to a larger window for therapeutic intervention with HAART, is associated with the establishment of a persistent specific HIV immune response resulting in a long-term viral control of vertically infected infants.
- Published
- 2008
- Full Text
- View/download PDF